Disrupting VE-cadherin Y685 phosphorylation inhibits development of experimental diabetic and prediabetic retinopathy
Journal of Clinical Investigation · 15.05.2026 · 136 (10)
DOI: 10.1172/jci195048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, online erschienen am 15.05.2026. Verfasst von Yixin Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Pharmacology Mannheim, European Center for Angioscience (ECAS). Hauptthemen laut MEDLINE: Diabetic Retinopathy, Cadherins, Antigens, CD, Prediabetic State. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Diabetic retinopathy involves early retinal vascular barrier breakdown and pericyte loss, yet the initiating molecular events remain poorly defined. Vascular endothelial cadherin (VE-cadherin), a key regulator of endothelial integrity, is notably reduced in diabetic and prediabetic nucleoside diphosphate kinase B–deficient (NDPKB-deficient) mouse retinas, particularly in the retinal deep capillary layer, and this decline precedes pericyte loss. In vitro, high glucose (HG) and NDPKB deficiency induced VE-cadherin Y685 phosphorylation, promoting its junctional internalization, activating the hexosamine biosynthesis pathway, and increasing angiopoietin 2 (Ang2), resulting in impaired endothelial barrier function and disrupting pericyte attachment. Preventing Y685 phosphorylation through VE-cadherin Y685F mutation blocked these HG- and NDPKB-driven pathological effects. Pharmacological intervention experiments identified protein O-linked β-N-acetyl glucosamine (O-GlcNAc) modification as a mediator of Y685-dependent Ang2 upregulation. In vivo, VE-cadherin Y685F-knockin mice were protected from diabetes- and prediabetes-induced vascular hyperpermeability, exhibited reduced protein O-GlcNAcylation and Ang2 induction, and maintained neuronal function. O-GlcNAc–enriched retinal proteomics further showed that the Y685F mutation restored balanced neurovascular and mitochondrial pathways. These findings highlight the potential of targeting VE-cadherin Y685 phosphorylation as a promising therapeutic approach to maintain retinal vascular integrity and attenuate the pathological progression of diabetic and prediabetic retinopathy. Disrupting a harmful protein change protects retinal blood vessels in diabetes, reducing leakage and preventing loss of supportive cells that keep vessels stable and healthy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Experimental Pharmacology Mannheim, European Center for Angioscience (ECAS).
- Department of Cardiovascular Genomics and Epigenomics, ECAS; and.
- 5th Medical Clinic, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
Förderung
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Wang, Y., Huang, H., Shao, F., Eshwaran, R., Qin, M., Karim, N., Ren, Y., Dobreva, G., Hammes, H. P., Wieland, T., & Feng, Y. (2026). Disrupting VE-cadherin Y685 phosphorylation inhibits development of experimental diabetic and prediabetic retinopathy. Journal of Clinical Investigation, 136(10). https://doi.org/10.1172/jci195048
Vancouver
Wang Y, Huang H, Shao F, Eshwaran R, Qin M, Karim N, et al. Disrupting VE-cadherin Y685 phosphorylation inhibits development of experimental diabetic and prediabetic retinopathy. Journal of Clinical Investigation. 2026;136(10). doi:10.1172/jci195048
BibTeX
@article{Wang2026,
author = {Wang, Yixin and Huang, Hongpeng and Shao, Feng and Eshwaran, Rachana and Qin, Miao and Karim, Noor and Ren, Yonggang and Dobreva, Gergana and Hammes, Hans-Peter and Wieland, Thomas and Feng, Yuxi},
title = {Disrupting VE-cadherin Y685 phosphorylation inhibits development of experimental diabetic and prediabetic retinopathy},
journal = {Journal of Clinical Investigation},
year = {2026},
volume = {136},
number = {10},
doi = {10.1172/jci195048}
}
EUVIMED